Core Viewpoint - CICC has downgraded Weigao's net profit estimates for 2025 and 2026 by 7% to RMB 19.89 billion and RMB 21.83 billion respectively, while introducing a net profit estimate of RMB 23.48 billion for 2027, maintaining a target price of HKD 6.40 and an outperform rating, indicating a potential upside of 22.4% [1] Group 1 - Weigao announced a reasonable exchange price for the share swap transaction with Weigao Blood Products, which will result in Weigao controlling Weigao Blood Products [2] - The final valuation for Weigao Purui was confirmed at RMB 8.511 billion, with the share swap involving 272 million shares, representing 65.11% of Weigao Blood Products' current issued shares [2] - After the transaction, Weigao's stake in Weigao Blood Products will increase from 23.53% to 51.35%, making Weigao Blood Products a subsidiary of Weigao [2] Group 2 - Weigao Purui's profit commitment is set at RMB 6.39 billion, RMB 7.20 billion, and RMB 7.84 billion for 2026 to 2028, with a compound annual growth rate (CAGR) of 10.7% [3] - If the transaction is delayed until 2027, the profit commitments for Weigao Purui will be RMB 7.20 billion, RMB 7.84 billion, and RMB 8.45 billion for 2027 to 2029, with a CAGR of 8.3% [3] Group 3 - Weigao Blood Products focuses on dialysis consumables and equipment, while Weigao Purui specializes in pre-filled delivery systems and automatic safety delivery systems, creating synergies in the biopharmaceutical upstream market [4] - The upstream biopharmaceutical market in China is projected to reach RMB 21.2 billion in 2024, with an expected growth to RMB 40.6 billion by 2030, reflecting a CAGR of 11.5% and significant potential for domestic substitution [4]

Group 1 - The core viewpoint of the report is that the company Weigao Co., Ltd. (01066) has its net profit estimates for 2025 and 2026 revised down by 7% to 19.89 billion yuan and 21.83 billion yuan respectively, while introducing a net profit estimate of 23.48 billion yuan for 2027. The current stock price corresponds to a P/E ratio of 9.9x for 2026 and 8.9x for 2027, with a target price maintained at 6.40 HKD, indicating a potential upside of 22.4% based on a sector valuation increase [1][2]. Group 2 - On January 5, 2026, Weigao Co., Ltd. announced the progress of a share swap transaction with Weigao Blood Products (603014), which is deemed reasonable. Following the transaction, Weigao Co., Ltd. will hold a controlling stake in Weigao Blood Products. The final valuation for Weigao Purui was confirmed at 8.511 billion yuan, corresponding to a static P/E of 14.66x for 2024, with the share swap involving 272 million shares, representing 65.11% of the current issued shares of Weigao Blood Products [2][3]. Group 3 - Weigao Co., Ltd. has made a cautious and reasonable profit commitment for Weigao Purui, projecting net profits of 639 million yuan, 720 million yuan, and 784 million yuan for the years 2026 to 2028, reflecting a compound annual growth rate (CAGR) of 10.7%. If the transaction is delayed until 2027, the profit commitments for 2027 to 2029 will be 720 million yuan, 784 million yuan, and 845 million yuan, with a CAGR of 8.3% [3]. Group 4 - Weigao Blood Products and Weigao Purui are expected to have synergistic effects as they jointly expand into the upstream biopharmaceutical market. Weigao Blood Products focuses on consumables and equipment for blood dialysis and peritoneal dialysis, while Weigao Purui specializes in pre-filled delivery systems and automatic safety delivery systems for vaccine, antibody, and recombinant protein pharmaceutical companies. The upstream biopharmaceutical market in China is projected to reach 21.2 billion yuan in 2024, with an expected growth to 40.6 billion yuan by 2030, reflecting a CAGR of 11.5% and significant potential for domestic substitution due to low localization rates [4].